ACH-1095 is a novel-mechanism NS4A antagonist being developed for the $4B HCV market.

ACH-1625 is a potent inhibitor of HCV NS3 protease with good toxicology, a unique PK profile, and strong potential for once-daily dosing.

ACH-702 is a
broad-spectrum bactericidal orally available compound for $2B serious bacterial infections market with a novel target profile against bacterial DNA replication enzymes.

ELVUCITABINE is a HIV nucleoside for the $3.7B NRTI market that has demonstrated potent antiviral activity, including against HIV strains resistant to other NRTIs.